-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Nuo9RQgGlGZSctV57wwUedYQo4AUAeAGa7qK34NNmdiV+An25b3vrekC6gW35Eos GTUo4liG0mGNAI+fQmvbtQ== 0001140361-07-019748.txt : 20071015 0001140361-07-019748.hdr.sgml : 20071015 20071015195344 ACCESSION NUMBER: 0001140361-07-019748 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20071011 FILED AS OF DATE: 20071015 DATE AS OF CHANGE: 20071015 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KV PHARMACEUTICAL CO /DE/ CENTRAL INDEX KEY: 0000057055 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 430618919 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 2503 S HANLEY RD CITY: ST LOUIS STATE: MO ZIP: 63144 BUSINESS PHONE: 3146456600 MAIL ADDRESS: STREET 1: 2503 S HANLEY RD CITY: ST LOUIS STATE: MO ZIP: 63144 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Van Vliet David A CENTRAL INDEX KEY: 0001296310 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09601 FILM NUMBER: 071172957 BUSINESS ADDRESS: BUSINESS PHONE: 314-645-6600 MAIL ADDRESS: STREET 1: 1105 SANCTUARY PKWY, STREET 2: SUITE 210 CITY: ALPHARETTA STATE: 2Q ZIP: 30004 4 1 doc1.xml FORM 4 X0202 4 2007-10-11 0 0000057055 KV PHARMACEUTICAL CO /DE/ KVA / KVB 0001296310 Van Vliet David A 2503 SOUTH HANLEY ROAD ST. LOUIS MO 63144 1 1 0 0 Chief Administration Officer Option to Purchase 25.23 2007-10-11 4 D 0 5000 D 2009-06-29 Class B Common Stock 5000 0 D Option to Purchase 25.25 2007-10-11 4 A 0 5000 A 2009-06-29 Class B Common Stock 5000 5000 D Option to Purchase 17.85 2007-10-11 4 D 0 2500 D 2009-09-10 Class B Common Stock 2500 0 D Option to Purchase 18.42 2007-10-11 4 A 0 2500 A 2009-09-10 Class B Common Stock 2500 2500 D Option to Purchase 16.79 2007-10-11 4 D 0 2500 D 2010-11-01 Class A Common Stock 2500 0 D Option to Purchase 19.99 2007-10-11 4 A 0 2500 A 2010-11-01 Class A Common Stock 2500 2500 D These two reported transactions involve an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 29, 2004 and provides for a vesting of 20% on date of grant and in 20% increments on each anniversary date thereafter. These two reported transactions involve an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on September 10, 2004 and provides for a vesting of 20% on date of grant and in 20% increments on each anniversary date thereafter. These two reported transactions involve an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 1, 2005 and provides for a vesting of 20% on date of grant and in 20% increments on each anniversary date thereafter. /s/ Richard H. Chibnall, Attorney-in-Fact 2007-10-15 EX-24.1 2 poa1.htm POWER OF ATTORNEY Unassociated Document
POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Richard H. Chibnall and Gerald R. Mitchell, as the true and lawful attorney-in-fact and agent of the undersigned, with full power of substitution and resubstitution, for the undersigned and in the name, place and stead of the undersigned, in any and all capacities, to: (i) sign any and all Forms 3, and 4 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission; (ii) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, or 4 and timely file such form with the Securities and Exchange Commission and any stock exchange or similar authority; and (iii) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact and agent, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact and agent on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact and agent may approve in the discretion of such attorney-in-fact and agent.

The undersigned hereby further grants unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in person hereby ratifying and confirming all said attorney-in-fact and agent or substitute may lawfully do or cause to be done by virtue hereof. The undersigned acknowledges that the attorney-in-fact and agent, in serving in such capacities at the request of the undersigned, is not assuming, nor is K-V Pharmaceutical Company (the “Company”) assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer (a) an officer and/or director of the Company or (b) required to file Forms 3 and 4 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless in either case earlier revoked by the undersigned in a signed writing delivered to the attorney-in-fact and agent.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 24th day of November, 2005.


 
/s/ David A. Van Vliet


-----END PRIVACY-ENHANCED MESSAGE-----